Skip to main
BNTX

BioNTech SE (BNTX) Stock Forecast & Price Target

BioNTech SE (BNTX) Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 55%
Buy 27%
Hold 18%
Sell 0%
Strong Sell 0%

Bulls say

BioNTech's financial position is robust, as the company reported approximately €16.7 billion in cash and cash equivalents, which provides significant liquidity for ongoing research and development initiatives. The incremental positive news regarding BNT323 highlights the potential for successful advancements in its oncology pipeline, particularly in the Phase 3 DYNASTY-Breast02 trial focused on breast cancer treatments. Additionally, the preclinical data showing the effectiveness of the LP.8.1-adapted COVID-19 vaccine against various circulating SARS-CoV-2 sublineages underscores the company's capacity to innovate and respond to emerging health challenges, further strengthening its market position.

Bears say

BioNTech faces substantial risks that negatively impact its stock outlook, including the potential for negative data across several key oncology drug candidates, slower-than-expected market uptake, and challenges in advancing programs on schedule. The company's financial performance further underscores this sentiment, as it recorded a net loss per diluted share of €0.12 in Q3 2025, with projections indicating a full-year net loss per diluted share of €3.99. Additionally, evolving dynamics in the COVID-19 vaccine market, particularly influenced by new regulatory environments, may divert investor focus from the company’s oncology portfolio, heightening concerns about its operational stability and long-term viability.

BioNTech SE (BNTX) has been analyzed by 11 analysts, with a consensus rating of Buy. 55% of analysts recommend a Strong Buy, 27% recommend Buy, 18% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of BioNTech SE and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About BioNTech SE (BNTX) Forecast

Analysts have given BioNTech SE (BNTX) a Buy based on their latest research and market trends.

According to 11 analysts, BioNTech SE (BNTX) has a Buy consensus rating as of Feb 4, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $140.31, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $140.31, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

BioNTech SE (BNTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.